MedTrace Logo

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

NCT04235621 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-07-20

No results posted yet for this study

Summary

This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine will be collected approximately every 2 weeks for 8 weeks. Patients may participate in Part 1, Part 2, or both, and will be followed for up to 1 year consisting of data collection from the patient's medical records and home collection of urine samples every 4 months.

Conditions

  • Glomerulosclerosis, Focal Segmental
  • Minimal Change Disease
  • Diabetic Nephropathies

Interventions

OTHER

FSGS/TR-MCD

This is a non-interventional study

OTHER

Diabetic Nephropathy (DN)

This is a non-interventional study

Sponsors & Collaborators

  • Goldfinch Bio, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-20
Primary Completion
2020-05-27
Completion
2020-05-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04235621 on ClinicalTrials.gov